CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of May 20, 2026, CRSP trades at $48.31 with a market cap of $4.68B and a P/E ratio of -7.51. CRSP moved +2.03% today. Year to date, CRSP is -11.97%; over the trailing twelve months it is +23.69%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $75.00. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CRSP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CRSP recently traded at $48.31. Market cap is $4.68B. P/E ratio is -7.51. Revenue is $3.51M.
| Metric | Value |
|---|---|
| Price | $48.31 |
| Market Cap | $4.68B |
| P/E Ratio | -7.51 |
| EPS | $-6.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.48 |
| 52-Week Low | $30.04 |
| Volume | 1.52M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.51M |
| Net Income | $-581.60M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.51M | $-581.60M | $-6.47 |
| 2024 | $37.31M | $-366.25M | $-4.34 |
| 2023 | $371.21M | $-153.61M | $-1.94 |
| 2022 | $1.20M | $-650.17M | $-8.36 |
14 analysts cover CRSP: 0 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $75.00.